Focus: Compass Therapeutics is a Boston-based public biotech focused on antibody therapies for oncology and neurology, currently in early-stage clinical development with minimal revenue.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Compass presents a high-risk, pre-revenue opportunity best suited for scientists willing to bet on psychedelic psychiatry and antibody oncology but should expect financial volatility and limited near-term stability.
Help build intelligence for Compass Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Compass Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Path To Profitability - Yahoo Finance
Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Path To Profitability Yahoo Finance
Compass Therapeutics, Inc. (CMPX) Up 200% Year-on-Year - Yahoo Finance
Compass Therapeutics, Inc. (CMPX) Up 200% Year-on-Year Yahoo Finance
Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster - Fierce Biotech
Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster Fierce Biotech
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from Brokerages MarketBeat
ABL Bio secures US orphan status for cholangiocarcinoma drug Torbeximig - CHOSUNBIZ - Chosunbiz
ABL Bio secures US orphan status for cholangiocarcinoma drug Torbeximig - CHOSUNBIZ Chosunbiz
ABL Bio Partner Compass Wins FDA Orphan Drug Status for Bile Duct Cancer Drug Tovesimig - Seoul Economic Daily
ABL Bio Partner Compass Wins FDA Orphan Drug Status for Bile Duct Cancer Drug Tovesimig Seoul Economic Daily
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo